HEADS UP!***BSDM*** IS ABOUT TO MAKE SOME REAL EARNINGS...
TherMatrx Receives FDA Approval for New BPH Therapy
SALT LAKE CITY, Jul 3, 2001 /PRNewswire via COMTEX/ -- BSD Medical Corp. (OTC Bulletin Board: BSDM chart, msgs) announced today that TherMatrx, Inc., in which it has 30% ownership, has received FDA approval to begin marketing its TMx-2000(TM) transurethral microwave thermotherapy system for treating benign prostatic hyperplasia (BPH).
BPH is a condition resulting from enlargement of the prostate, with symptoms such as increased urinary frequency, incontinence, nocturia, urgency or slow urinary stream. Over fifty percent of men are afflicted by BPH by age 60, and as many as 90% have symptoms by the time they are 70 or 80. BPH is a major health problem, and the limited alternatives for its treatment present the risk of significant side effects.
The three-year, 200 patient, multi-center Phase III clinical study presented to the FDA by TherMatrx demonstrated highly significant improvements in patient symptoms with minimal side effects and excellent patient tolerance. With its patient-friendly profile and ease of use in the physician's office, the TMx-2000(TM) offers a first line treatment option for men suffering from BPH.
The Health Finance Administration (HCFA) has already granted substantial reimbursement for transurethral microwave thermotherapy, making it possible for TherMatrx to quickly enter the market using a direct sales force already in place. In 1997, BSD Medical entered into an agreement with Oracle Strategic Partners and Charles Manker to form TherMatrx, Inc., a Chicago-based company focused on minimally invasive treatment of non-cancerous urologic diseases.
As the pioneer in microwave thermotherapy, TherMatrx patents are licensed by Urologix, Inc. for their Targis and Prostatron systems. Hyrum A. Mead, President of BSD Medical said, "Microwave thermotherapy is an excellent therapy that has suffered from some missteps in the marketplace to date. We believe TherMatrx has addressed the problems associated with the current microwave thermotherapy systems and is nicely positioned to be the dominant player in this market. Based on projections for TherMatrx and the capital value of Urologix, we believe that our ownership in TherMatrx can rather quickly become a very substantial asset."
For further information about TherMatrx, Inc., visit the TherMatrx web site at www.thermatrx.com. For information about BSD Medical, or to find hyperthermic oncology information sources and treatment centers, visit the BSD web site (www.bsdmc.com).
Statements contained in this press release that are not historical facts are forward looking statements, as that item is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties (detailed in the Company's filings with the Securities and Exchange Commission) that could cause actual results to differ materially from estimated results. |
